Autoantibody profiling in APS

D. Roggenbuck, V. Somma, P. Schierack, M. O. Borghi, P. L. Meroni

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The international consensus for the classification of antiphospholipid syndrome (APS) requires clinical and laboratory criteria to be considered at an equal level for diagnosing APS. Thus, detection of antiphospholipid antibodies (aPL) being a hallmark of APS has been the object of intensive investigation over the past 40 years. However, appropriate detection of aPL still remains a laboratory challenge due to their heterogeneity comprising autoantibodies reactive to different phospholipid-binding plasma proteins, such as beta-2 glycoprotein I (β2GPI) and prothrombin. The relevance of aPL interacting with phospholipids other than cardiolipin (CL, diphosphatidylglycerol), such as phosphatidylserine (PS), remains elusive with regard to the diagnosis of APS. Recently, the concept of aPL profiling has been introduced to assess the risk of thrombotic complications in patients with APS. New assay techniques, apart from enzyme-linked immunosorbent assays (ELISAs) recommended by the international consensus for the classification of APS, have been proposed for multiplexing of aPL testing. Line immunoassays (LIAs) employing a novel hydrophobic solid phase for the simultaneous detection of different aPL seem to be an intriguing alternative. We evaluated a novel multiplex LIA employing a hydrophobic membrane coated with different phospholipid (PL)-binding proteins or PLs. The performance characteristics of this new multiplexing assay technique demonstrated its usefulness for aPL profiling.

Original languageEnglish
Pages (from-to)1262-1264
Number of pages3
JournalLupus
Volume23
Issue number12
DOIs
Publication statusPublished - Oct 8 2014

Fingerprint

Antiphospholipid Antibodies
Antiphospholipid Syndrome
Autoantibodies
Phospholipids
Cardiolipins
Immunoassay
Carrier Proteins
beta 2-Glycoprotein I
Phosphatidylserines
Prothrombin
Blood Proteins
Enzyme-Linked Immunosorbent Assay
Membranes

Keywords

  • antiphospholipid antibody
  • Antiphospholipid syndrome
  • line immunoassay

ASJC Scopus subject areas

  • Rheumatology
  • Medicine(all)

Cite this

Roggenbuck, D., Somma, V., Schierack, P., Borghi, M. O., & Meroni, P. L. (2014). Autoantibody profiling in APS. Lupus, 23(12), 1262-1264. https://doi.org/10.1177/0961203314534305

Autoantibody profiling in APS. / Roggenbuck, D.; Somma, V.; Schierack, P.; Borghi, M. O.; Meroni, P. L.

In: Lupus, Vol. 23, No. 12, 08.10.2014, p. 1262-1264.

Research output: Contribution to journalArticle

Roggenbuck, D, Somma, V, Schierack, P, Borghi, MO & Meroni, PL 2014, 'Autoantibody profiling in APS', Lupus, vol. 23, no. 12, pp. 1262-1264. https://doi.org/10.1177/0961203314534305
Roggenbuck D, Somma V, Schierack P, Borghi MO, Meroni PL. Autoantibody profiling in APS. Lupus. 2014 Oct 8;23(12):1262-1264. https://doi.org/10.1177/0961203314534305
Roggenbuck, D. ; Somma, V. ; Schierack, P. ; Borghi, M. O. ; Meroni, P. L. / Autoantibody profiling in APS. In: Lupus. 2014 ; Vol. 23, No. 12. pp. 1262-1264.
@article{dc5877be7dc64d69994b8ff67bfeec70,
title = "Autoantibody profiling in APS",
abstract = "The international consensus for the classification of antiphospholipid syndrome (APS) requires clinical and laboratory criteria to be considered at an equal level for diagnosing APS. Thus, detection of antiphospholipid antibodies (aPL) being a hallmark of APS has been the object of intensive investigation over the past 40 years. However, appropriate detection of aPL still remains a laboratory challenge due to their heterogeneity comprising autoantibodies reactive to different phospholipid-binding plasma proteins, such as beta-2 glycoprotein I (β2GPI) and prothrombin. The relevance of aPL interacting with phospholipids other than cardiolipin (CL, diphosphatidylglycerol), such as phosphatidylserine (PS), remains elusive with regard to the diagnosis of APS. Recently, the concept of aPL profiling has been introduced to assess the risk of thrombotic complications in patients with APS. New assay techniques, apart from enzyme-linked immunosorbent assays (ELISAs) recommended by the international consensus for the classification of APS, have been proposed for multiplexing of aPL testing. Line immunoassays (LIAs) employing a novel hydrophobic solid phase for the simultaneous detection of different aPL seem to be an intriguing alternative. We evaluated a novel multiplex LIA employing a hydrophobic membrane coated with different phospholipid (PL)-binding proteins or PLs. The performance characteristics of this new multiplexing assay technique demonstrated its usefulness for aPL profiling.",
keywords = "antiphospholipid antibody, Antiphospholipid syndrome, line immunoassay",
author = "D. Roggenbuck and V. Somma and P. Schierack and Borghi, {M. O.} and Meroni, {P. L.}",
year = "2014",
month = "10",
day = "8",
doi = "10.1177/0961203314534305",
language = "English",
volume = "23",
pages = "1262--1264",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "12",

}

TY - JOUR

T1 - Autoantibody profiling in APS

AU - Roggenbuck, D.

AU - Somma, V.

AU - Schierack, P.

AU - Borghi, M. O.

AU - Meroni, P. L.

PY - 2014/10/8

Y1 - 2014/10/8

N2 - The international consensus for the classification of antiphospholipid syndrome (APS) requires clinical and laboratory criteria to be considered at an equal level for diagnosing APS. Thus, detection of antiphospholipid antibodies (aPL) being a hallmark of APS has been the object of intensive investigation over the past 40 years. However, appropriate detection of aPL still remains a laboratory challenge due to their heterogeneity comprising autoantibodies reactive to different phospholipid-binding plasma proteins, such as beta-2 glycoprotein I (β2GPI) and prothrombin. The relevance of aPL interacting with phospholipids other than cardiolipin (CL, diphosphatidylglycerol), such as phosphatidylserine (PS), remains elusive with regard to the diagnosis of APS. Recently, the concept of aPL profiling has been introduced to assess the risk of thrombotic complications in patients with APS. New assay techniques, apart from enzyme-linked immunosorbent assays (ELISAs) recommended by the international consensus for the classification of APS, have been proposed for multiplexing of aPL testing. Line immunoassays (LIAs) employing a novel hydrophobic solid phase for the simultaneous detection of different aPL seem to be an intriguing alternative. We evaluated a novel multiplex LIA employing a hydrophobic membrane coated with different phospholipid (PL)-binding proteins or PLs. The performance characteristics of this new multiplexing assay technique demonstrated its usefulness for aPL profiling.

AB - The international consensus for the classification of antiphospholipid syndrome (APS) requires clinical and laboratory criteria to be considered at an equal level for diagnosing APS. Thus, detection of antiphospholipid antibodies (aPL) being a hallmark of APS has been the object of intensive investigation over the past 40 years. However, appropriate detection of aPL still remains a laboratory challenge due to their heterogeneity comprising autoantibodies reactive to different phospholipid-binding plasma proteins, such as beta-2 glycoprotein I (β2GPI) and prothrombin. The relevance of aPL interacting with phospholipids other than cardiolipin (CL, diphosphatidylglycerol), such as phosphatidylserine (PS), remains elusive with regard to the diagnosis of APS. Recently, the concept of aPL profiling has been introduced to assess the risk of thrombotic complications in patients with APS. New assay techniques, apart from enzyme-linked immunosorbent assays (ELISAs) recommended by the international consensus for the classification of APS, have been proposed for multiplexing of aPL testing. Line immunoassays (LIAs) employing a novel hydrophobic solid phase for the simultaneous detection of different aPL seem to be an intriguing alternative. We evaluated a novel multiplex LIA employing a hydrophobic membrane coated with different phospholipid (PL)-binding proteins or PLs. The performance characteristics of this new multiplexing assay technique demonstrated its usefulness for aPL profiling.

KW - antiphospholipid antibody

KW - Antiphospholipid syndrome

KW - line immunoassay

UR - http://www.scopus.com/inward/record.url?scp=84908672916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908672916&partnerID=8YFLogxK

U2 - 10.1177/0961203314534305

DO - 10.1177/0961203314534305

M3 - Article

C2 - 25228721

AN - SCOPUS:84908672916

VL - 23

SP - 1262

EP - 1264

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 12

ER -